USES CASES AND INFORMATION MODELS FOR SURPASS

WP3 developed the main use cases in the implementation of SurPass to create a SurPass v2.0 for survivors (including the TS and SCP), with actions to generate, validate, access and update the SurPass, where HCPs and CCS are users.

Information models for SurPass v2.0 were created, with variable types mapped to information items.

Information item Variable type
Treatment Summary
Medical History Genetic diseases
Comorbidities
Cancer Diagnosis Date
Histopathology (optional link to full report)
Topography (optional link to full report)
Cancer Diagnosis Surgical intervention
Chemotherapy
Stem cell transplantation
Immunotherapy
Radiotherapy
Name of frontline protocol
Guidelines/Recommendations International Late Effects of Childhood Cancer Guideline Harmonization Group
PanCareFollowUp (PCFU) Guidelines Working Group
SCP and other LTFU data Organizational aspects of the LTFU setting
the personnel involved
the components (which screening tests) of the LTFU
the time the LTFU should be initiated and the intervals between the visits (Frequency)
Follow-up for Malignant Events Screening tests for other malignant LEs (second, subsequent Malignant Neoplasms (SMN))
Medical visits
Imaging or laboratory tests
Intervals of screenings
Actions to take in case results are not within normal range
Follow-up for non-Malignant Events System or organ at risk
Disorder
Medical visits
Intervals of screening
Actions to take in case results are not within normal range

From here, extensive work was done in each country to develop more detailed use cases, following a methodology that could be applied in new settings in future. 

The summary above about the use cases and information model will be made available on the PanCare website in the Toolkit. Clinics implementing the SurPass in future will be provided with further details by the SurPass provider to develop tailored use cases to support implementation.

Disclaimer

PanCare strives to provide accurate and complete information that is up-to-date as of the date of publication.

No warranty or representation, expressed or implied, is made concerning the accuracy, reliability, completeness, relevance, or timeliness of this information.

The PanCare materials are free to use for anyone aiming to inform about late effects and long-term survivorship care. However, no financial advantage may be achieved. All communication should reference PanCare and link to the PanCare website.

PanCareSurPass has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 899999. The material presented and views expressed here are the responsibilities of the author(s) only. The EU Commission takes no responsibility for any use made of the information set out.